VolitionRx Limited (NYSE:VNRX) (“Volition”), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.
Volition’s major achievements in 2023 include:
- Launching the Nu.Q® Vet Cancer Test in some significant markets through several licensing, supply and/or distribution agreements.
- Establishing several agreements to further expand access to the Nu.Q® Vet Cancer Test on a worldwide basis in 2024.
- Driving a market access program for Nu.Q® NETs, working with Centers of Excellence globally to exemplify its clinical utility.
- Completing the Q-Sub process with the U.S. Food and Drug Administration, and establishing a clear regulatory pathway for Nu.Q® NETs.
- Announcing a breakthrough early cancer detection method.
- Continuing to strengthen our strategic patent portfolio.
- Scaling up its operations, in particular production capacity.
To find out more about these achievements, please read Volition’s Business Review here or watch the video below.
Video – https://www.youtube.com/watch?v=YF_DAUp45Sc
Cameron Reynolds, President and Group Chief Executive Officer, said: “At Volition, we are dedicated to saving lives and improving outcomes for people and animals worldwide through our novel epigenetics platform.
“We believe we made great progress in our mission throughout 2023 and have in place compelling plans to move forward in 2024.”
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals. For more information about Volition’s technology go to: www.volition.com
